Biotechnology specialist (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics.

Overall, the quarter demonstrated Amgen's effective execution amid a competitive landscape.

Source: Amgen. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.

Continue reading

Source Fool.com